OSOscar G. Segurado

Oscar G. Segurado

*This is an algorithmically generated author record based on publicly available information.

Oscar G. Segurado has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Abstract 3652: Analytical validation of a novel circulating tumor DNA detection platform for targeted and immunotherapy selection

    by Pratyush Gupta, Julian Lucas, Alex Atkins, Wen-Sy Tsai, Twinkal Marfatia, Shih-En Chang, Oscar Segurado, Rui Mei

    Introduction Comprehensive genomic profiling of solid tumors using circulating tumor DNA (ctDNA) has enabled the detection of all NCCN guideline-recommended somatic genomic classes of alterations from a single, non-invasive blood draw. However, current ctDNA tests still face two major challenges: the inability to reliably identify somatic variants at low mutant allele fraction (MAF), and inconsistency in how the tests have been validated. This study shows how the Single Molecule Sequencing (SMSEQ) platform addresses these challenges. The platform integrates innovative ctDNA extraction methodology, highly optimized library preparation and an error-based variant-calling algorithm to drastically improve sensitivity and specificity. The platform analyzes 5 classes of somatic variants: single nucleotide variants (SNVs), insertions and deletions (Indels), copy number variants (CNVs), fusions and microsatellite instability (MSI). Methods We analyzed a 73 gene panel covering NCCN recommended actionable variants for solid tumors in 60 reference ctDNA samples with known variants to establish the limit of detection, sensitivity, specificity, accuracy and reproducibility of the SMSEQ platform. For clinical validation, we tested 36 patients with metastatic colorectal cancer (mCRC) and 34 healthy controls from the Chang Gung Memorial Hospital, and 227 patients diagnosed with solid tumor from Taiwan. Circulating DNA was extracted from plasma followed by library preparation using a highly optimized NGS workflow. Somatic variants in ctDNA are identified using locus-specific modeling to separate tumor variants from normal errors. Results Validation according to recently published ACMG/AMP guidelines shows that the SMSEQ platform allows calling of variants with >99.999% analytical specificity for SNVs, Indels and fusions; and >99% analytical specificity for CNVs and MSI. The platform successfully detected variants at low MAF: 0.1% for SNVs and Indels, Citation Format: Pratyush Gupta, Julian Lucas, Alex Atkins, Wen-Sy Tsai, Twinkal Marfatia, Shih-En Chang, Oscar Segurado, Rui Mei. Analytical validation of a novel circulating tumor DNA detection platform for targeted and immunotherapy selection [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3652.

  • Abstract 2241: Comparison of rare pathogenic germline variants associated with cancer predisposition syndrome in Taiwan and USA populations

    by Zulfiqar Gulzar, Julian Lucas, Alex Atkins, Stephen Su, Oscar Segurado, Rui Mei

    Objective To evaluate the analytical performance of a 98-gene NGS panel designed to detect highly- penetrant, rare pathogenic germline variants, strongly linked to predisposition of cancers in Taiwan and USA. Methods This 98-gene panel was developed following an extensive review of genes with a strong clinical and genetic linkage evidence for cancer predisposition. Probes covering the exon sequences from these 98 genes were validated using 19 samples obtained from the Platinum Genomes Project and the Genome In A Bottle Consortium. Analytical sensitivity and specificity for the detection of clinically important variants within multiple cancers types were demonstrated in 30 reference samples derived from patients with familial cancers. Additionally, two clinical cohorts of 1885 and 374 subjects from Taiwan and USA, respectively, were screened for detection of rare pathogenic germline variants in our CAP accredited laboratory in Taiwan, and CLIA certified laboratory in the USA. Results The analytical sensitivity and specificity of the assay panel were 99.95% and 100%, respectively. Similarly, the reportable variants for all 30 DNA samples containing clinically important SNVs in BRCA1/2, RET, APC, MEN1 and PTEN were called with no false positives. The concordance for the use of either blood (reference lab) or saliva (internal lab) as a sample source was found to be 99.9%. The mean age of the Taiwan cohort was 43, with 58% males and 42% females, while the US cohort had a mean age of 58 with 40% males and 60% females. Germline pathogenic variants were detected in 47/1885 (2.5%) and 25/374 (6.7%) individuals respectively. Outside of BRCA1 and BRCA2 positive cases in Taiwan (8.5% and 17%) and US (4% and 0%), the remaining germline positive cohort had pathogenic variants detected in MUTYH, MLH1, RET, ATM, APC, CHEK2, ERCC2, PALB2, PTCH1, WRN, BARD1, BRIP1, PMS2, PTEN, RAD51D, SDHD, RUNX1, BLM, HOXB13, and MSH6. Stratification of pathogenic variants among high risk and average risk individuals suggests these variants are distributed in both risk groups. Using a multigene approach, we identified 35/47 (87%) and 24/25 (96%) additional cases with rare pathogenic mutations respectively which would not have been identified if we were only looking for BRCA1/2 mutations. Conclusion We have demonstrated in 2 clinical cohorts the analytical and clinical validity of a 98-gene panel for the detection of pathogenic germline variants predisposing to cancer. High sensitivity and specificity of this panel was demonstrated irrespective of the use of blood or saliva as samples. Citation Format: Zulfiqar Gulzar, Julian Lucas, Alex Atkins, stephen Su, Oscar Segurado, Rui Mei. Comparison of rare pathogenic germline variants associated with cancer predisposition syndrome in Taiwan and USA populations [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2241.

  • Prospective clinical study of circulating tumor cells for colorectal cancer screening.

    by Wen-Sy Tsai, Ashish Nimgaonkar, Oscar Segurado, Ying Chang, Ben Hsieh, Hung-Jen Shao, Jen-Chia Wu, Jr-Ming Lai, Mana Javey, Drew Watson, et al.

    556 Background: Colorectal cancer (CRC) is among the most preventable cancers when precancerous lesions are detected at an early stage. Current screening methods for CRC require bowel prep or stool-based testing that are inconvenient, resulting in low compliance. Stool based tests have limited sensitivity for the detection of precancerous lesions. We have conducted a prospective clinical study over a period of > 3 years to assess a novel assay to detect and enumerate circulating tumor cells (CTCs) in a blood sample for early CRC detection. Methods: A single-center, IRB-approved, prospective and blinded clinical study was conducted in 620 subjects including 438 with adenoma, polyps or stage I-IV CRC and 182 healthy controls. For each subject, 2mL peripheral whole blood collected through a routine blood draw was processed using the CellMax biomimetic platform (CMx). The CMx test is a proprietary microfluidic biochip that minimizes non-specific binding and accurately enumerates CTCs. A multivariate analysis was performed to assess the clinical performance characteristics of the CMx test. Results: Disease status was evaluated by a standard clinical protocol which included colonoscopy and biopsy results. Probability of CRC risk was assessed by an age-adjusted regression model which correlated CTCs to clinical status. The CMx test’s overall accuracy was 88% for all stages of colorectal illness, including precancerous lesions. Conclusions: The study has demonstrated high accuracy for the detection of CRC using a novel CTC assay. It is the first study to show high sensitivity in the detection of precancerous colorectal lesions. The simple blood draw required can be easily integrated into a patient’s routine physical, increasing test compliance.[Table: see text]


  • Open Access

    Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia

    by Yvonne C. Lee, James Hackett, Michelle Frits, Christine K. Iannaccone, Nancy A. Shadick, Michael E. Weinblatt, Oscar G. Segurado, Eric H. Sasso

    Objectives. To examine the association between a multibiomarker disease activity (MBDA) score, CRP and clinical disease activity measures among RA patients with and without concomitant FM. Methods. In an observational cohort of patients with established RA, we performed a cross-sectional analysis comparing MBDA scores with CRP by rank correlation and cross-classification. MBDA scores, CRP and clinical measures of disease activity were compared between patients with RA alone and RA with concomitant FM (RA and FM) by univariate and multivariate analyses. Results. CRP was ⩽1.0 mg/dl for 184 of 198 patients (93%). MBDA scores correlated with CRP (r = 0.755, P < 0.001), but were often discordant, being moderate or high for 19%, 55% and 87% of patients with CRP ⩽0.1, 0.1 to ⩽0.3, or 0.3 to ⩽1.0 mg/dl, respectively. Among patients with CRP ⩽1.0 mg/dl, swollen joint count (SJC) increased linearly across levels of MBDA score, both with (P = 0.021) and without (P = 0.004) adjustment for CRP, whereas CRP was not associated with SJC. The 28-joint-DAS-CRP, other composite measures, and their non-joint-count component measures were significantly greater for patients with RA and FM (n = 25) versus RA alone (n = 173) (all P ⩽ 0.005). MBDA scores and CRP were similar between groups. Conclusion. MBDA scores frequently indicated RA disease activity when CRP did not. Neither one was significantly greater among patients with RA and FM versus RA alone. Thus, MBDA score may be a useful objective measure for identifying RA patients with active inflammation when CRP is low (⩽1.0 mg/dl), including RA patients with concomitant FM.


  • Cost-Effectiveness of Sequential Therapy with Tumor Necrosis Factor Antagonists in Early Rheumatoid Arthritis

    by Andrew Davies, Mary A. Cifaldi, Oscar G. Segurado, Michael H. Weisman

    Objective: To estimate the comparative lifetime cost-effectiveness of sequenced therapy with tumor necrosis factor (TNF) antagonists as the initial therapeutic intervention for patients with early rheumatoid arthritis (RA).Methods: Because patients with RA switch regimens many times throughout the course of disease, sequenced therapeutic interventions were modeled, continuing until the last effective agent failed or death occurred. The model used published clinical outcomes from short-term, randomized controlled trials. Direct treatment costs and costs of lost productivity were modeled for each of 5 alternative treatment sequences. Incremental cost-effectiveness ratios are expressed as quality-adjusted lifeyears (QALY) gained.Results: Treatment sequences that included TNF antagonists produced a greater number of QALY than conventional disease modifying antirheumatic drug regimens alone. The cost-effectiveness of sequenced therapy initiated with adalimumab plus methotrexate (MTX) extendedly dominated both infliximab-plus-MTX–initiated and etanercept sequences. The cost of adalimumab plus MTX per QALY was US $47,157 excluding productivity losses, and $19,663 including productivity losses. A supplementary sequence that incorporated adalimumab-plus-MTX–initiated first-line therapy followed by another TNF antagonist as second-line therapy was modeled; this sequence resulted in additional QALY gained and extendedly dominated all single-TNF strategies.Conclusion: Of the 3 single-TNF antagonist sequences, the adalimumab-plus-MTX–initiated sequence was cost-effective in producing the greatest number of QALY. Multiple TNF strategies, such as the supplementary sequence modeled in this analysis, may be cost-effective in producing even greater health gain.


  • HUMIRA®Pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab

    by Alan Kivitz, Oscar G Segurado

    The HUMIRA (adalimumab) Pen is a novel, integrated, disposable autoinjection delivery system for the subcutaneous injection of adalimumab. Adalimumab is a biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. Sustaining long-term efficacy with a biological therapy is influenced by patient adherence to the therapeutic regimen, which is often affected by the route of drug administration. Self-administered injectables offer several advantages over intravenous injections (i.e., portability, convenience and flexible scheduling). In particular, patients with chronic, debilitating diseases may need a self-administered medication available in an easy-to-use and convenient delivery device that minimizes pain and facilitates adherence to therapy. The adalimumab Pen offers these benefits and recent evidence indicates that patients overwhelmingly prefer the adalimumab Pen to the prefilled syringe.


  • Spanish laboratory backs off bid to cut research staff

    by Oscar G. Segurado

  • New DNA sequences for the human complement gene C4

    by Estela Paz-Artal, Alfredo Corell, Pilar Varela, Pablo Morales, Jose Manuel Martín Villa, Oscar G. Segurado, Miguel Alvarez, Antonio Arnalz Vlllena


  • Spain expands despite financial and logistical hurdles

    by Oscar G. Segurado